View
218
Download
0
Category
Preview:
Citation preview
1
Explanation of gradingThe recommendations regarding treatment initiation were graded as follows:
Grading Explanation
„Indicated“ Treatment is indicated
„should be initiated“ Treatment is generally indicated, but waiting is justifiable
„may be initiated“ Treatment is generally not indicated, but treatment initiation is justifiable
„not indicated“ Treatment is not indicated
The recommendations regarding choice of drugs were graded as follows:
Grading Explanation
„recommended“ Preferable Drug / combination
„alternative“ May be given, could be the best choice for some patients
„not recommended“ Only in special cases, but remains justifiable
„not indicated“ Should not be given
2
Symptoms CD4+ T-cells/µl
Additional criteria*
ART
HIV-associated symptoms and diseases(CDC: C, B), HIVAN, HAND
Any value-
Indicated
Asymptomatic (CDC: A)
<350 - indicated
350-500
Fulfilled indicated
- May be initiated
>500
Fulfilled should be initiated
Not fulfilled May be initiated
Acute retroviral syndrome with prolonged / severe symptoms
Any value - should be initiated
Asymptomatic/ mild symptoms during serokonversion
Any value - May be initiated
Treatment initiation
3
*Additional criteria for treatment initiation
• Pregnancy• Reduction of Infectiousness• Higher age• Chronic Hepatitis B and C Coinfection• Rapidly decreasing CD4+ cell count• Plasma viremia >100.000 copies/mL
• See: „Additional Aspects“:• High cardiovascular Risk (Framingham Score >20%/10 Yrs)
4
1 only for HLA-B*5701-negatives; Cave: possibly elevated cardiovascular risk, virologically slightly inferior leicht unterlegen
3 Cave: hepatotoxiicity increased in men with CD4+ count >400 and women with CD4+ count >250/µL4 Cave: not if HIV-RNA >100000 c/mL (not licensed)
Choice of drugs
2 not during pregnancy and in women with a desire to have children
(Cobicistat as an alternative for boosting of ATV and DRV discussed in the text)
Nucleoside/nucleotide analogue combinationsRecommended- Tenofovir/Emtricitabine- Abacavir/Lamivudine1
Alternative- Tenofovir / Lamivudine
NNRTIRecommended- Efavirenz²- Nevirapine³- Rilpivirine4
PIRecommended- Atazanavir/r- Darunavir/r- Lopinavir/rAlternative- Fosamprenavir
INIRecommended- Dolutegravir- Raltegravir- Elvitegravir/c (+TDF/FTC)
+
Combination partner 1 Combination partner 2
Recommended